Home>Topics>Stocks>Abiomed

Abiomed ABMD

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Abiomed's ( ABMD ) CEO Michael Minogue on Q1 2015 Results - Earnings Call Transcript

      Headlines

      Thu, 31 Jul 2014

      Start Time: 08:00 End Time: 08:52 Abiomed , Inc. (NASDAQ: ABMD ) Q1 2015 Earnings Conference Call July 31, 2014 ..... Good day, ladies and gentlemen. Welcome to the Abiomed , Inc. Q1 2015 Earnings Conference Call. At this

    2. Abiomed softens guidance after fiscal Q1 results

      Headlines

      Thu, 31 Jul 2014

      Abiomed ( ABMD -4.5% ) fiscal Q1 results : Total Revenues: $48.8M (+14.3%); Operating Expenses: $50.3M (+14.3%); Operating

    3. Premarket Gainers / Losers

      Headlines

      Thu, 31 Jul 2014

      QUIK -22% . DDD -13% . MTW -10% . VJET -10% . GLUU -9% . CODE -9% . ALU -9% . TTEK -9% . AKAM -7% . CTRP -7% . YUM -7% . LIQD -6% . OCN -6% . YPF -6% . WFM -6% . ABMD -6% . YELP -6% . VRX -5% . 1 comment!

    4. Abiomed EPS of -$0.04

      Headlines

      Thu, 31 Jul 2014

      Abiomed (NASDAQ: ABMD ): FQ1 EPS of -$0.04 may not be comparable to consensus of $0.02. Revenue of $48.8M (+14.4% Y/Y) misses by $0.82M . Press Release Post your comment!

    5. Notable earnings before Thursday’s open

      Headlines

      Wed, 30 Jul 2014

      AAWW , ABMD , ACIW , ACOR , ADP , AGI , ALKS , ALU , AMRC , APA , ASEI , ATK , AVP , AYR , AZN , BDX , BG , BGCP , BKCC , BLL , BUD , BWA

    6. A Young Power Couple's Kickstart Portfolio

      Headlines

      Fri, 6 Jun 2014

      Holding Market Value ($) Weight (%) Star Rating Matt's Roth IRA: Cash 5,263 1.96 N/A Matt's Roth IRA: Abiomed ABMD 184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals

    7. Dropping Coverage of Abiomed

      Commentary

      Wed, 18 Dec 2013

      We are no longer providing equity research on Abiomed . We provide broad coverage of more than 1,800 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    8. Abiomed Back on Track in 2Q, Following Weak Beginning of Fiscal Year

      Commentary

      Wed, 13 Nov 2013

      Abiomed reported strong fiscal second-quarter ..... largely consistent with our expectations. Abiomed remains on track to reach our full-year ..... continues to grow, which supports our view of Abiomed 's positive moat trend. We think there

    9. Abiomed Posts Weak First Quarter, but Our Fair Value Estimate Is Unchanged

      Commentary

      Thu, 1 Aug 2013

      Abiomed reported fiscal first-quarter performance ..... variance from quarter to quarter, we think Abiomed can still reach our full-year projections ..... nascent stage of the acute VAD market that Abiomed is still pioneering, we do not think the

    10. Thoratec Delivers Strong 2Q Following Anemic 1Q

      Commentary

      Thu, 1 Aug 2013

      unlikely to reach commercialization before 2017. Even though it will be several years before the PHP product is marketable, it nonetheless provides Thoratec with important entree to the acute VAD niche that is currently dominated by Abiomed .

    « Prev12345Next »
    Content Partners